Severe hypocalcaemia warning with osteoporosis drug
The adverse event typically occurs within weeks of starting denosumab therapy, regulators warn.
This article has been updated.
The US medicines regulator has slapped a boxed warning on the osteoporosis medication denosumab regarding the increased risk of severe hypocalcaemia in patients with advanced chronic kidney disease.
